Compare PURR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PURR | NVAX |
|---|---|---|
| Founded | 2025 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 1996 |
| Metric | PURR | NVAX |
|---|---|---|
| Price | $6.68 | $8.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | $8.15 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 7.4M | 3.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $148.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $3.01 | $6.20 |
| 52 Week High | $11.73 | $11.85 |
| Indicator | PURR | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 47.45 |
| Support Level | $5.75 | $7.70 |
| Resistance Level | $6.87 | $10.10 |
| Average True Range (ATR) | 0.33 | 0.29 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 67.83 | 75.00 |
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the largest HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to one of the largest and fastest growing revenue pools in digital assets.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.